NASDAQ:JSPRW Jasper Therapeutics (JSPRW) Stock Price, News & Analysis $0.01 0.00 (-10.60%) Closing price 05/19/2026 02:06 PM EasternExtended Trading$0.01 0.00 (-0.74%) As of 05/19/2026 05:00 PM Eastern Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Massive. Learn more. Add Compare Share Share Stock Analysis Stock AnalysisChartCompetitorsHeadlinesSEC FilingsShort InterestTrendsBuy This Stock About Jasper Therapeutics Stock (NASDAQ:JSPRW) View Price History Chart DataSkip Price History Chart 1 Day 5 Days 30 Days 90 Days 1 Year Advanced 1 Day 1 Day 5 Days 30 Days 90 Days 1 Year Advanced Show volume Show extended hours Get Jasper Therapeutics alerts:Sign Up Key Stats Today's Range$0.0116▼$0.015150-Day Range$0.01▼$0.0252-Week Range$0.01▼$0.18Volume4,745 shsAverage Volume20,025 shsMarket CapitalizationN/AP/E RatioN/ADividend YieldN/APrice TargetN/AConsensus RatingN/A Company Overview Jasper Therapeutics, Inc. is a clinical‐stage biopharmaceutical company focused on developing a new generation of cellular therapeutics for severe diseases. The company’s mission centers on harnessing targeted biological agents and engineered cell platforms to improve outcomes in hematopoietic stem cell transplantation, oncology and gene therapies. By advancing novel approaches to conditioning regimens and cell engineering, Jasper aims to address limitations of existing treatments, including toxicity, graft failure and restricted applicability. The company’s lead candidate, JSP191, is a humanized monoclonal antibody targeting the CD117 receptor on hematopoietic stem cells. JSP191 is designed to enable safer, more precise conditioning prior to stem cell transplantation and in vivo gene therapy by selectively depleting endogenous stem cells while sparing other bone marrow elements. Jasper is also exploring additional cell engineering programs that leverage proprietary platforms to develop next-generation cell therapies, including targeted immunotherapies and regenerative medicine applications. Headquartered in Boston, Massachusetts, Jasper Therapeutics conducts research and development activities in North America and collaborates with academic institutions and industry partners to advance its pipeline. The company’s leadership team brings experience in biologics development, clinical operations and cell therapy manufacturing, positioning Jasper to navigate the regulatory landscape and scale its technologies for broader patient access. Through strategic alliances and a focus on translational science, Jasper aims to move its most promising candidates toward pivotal clinical milestones.AI Generated. May Contain Errors. Read More Receive JSPRW Stock News and Ratings via Email Sign-up to receive the latest news and ratings for Jasper Therapeutics and its competitors with MarketBeat's FREE daily newsletter. Submit View SMS TermsSMS is currently available in Australia, Belgium, Canada, France, Germany, Ireland, Italy, New Zealand, the Netherlands, Singapore, South Africa, Spain, Switzerland, the United Kingdom, and the United States. By entering your phone number and clicking the sign-up button, you agree to receive periodic text messages from MarketBeat at the phone number you submitted, including texts that may be sent using an automatic telephone dialing system. Message and data rates may apply. Message frequency will vary. Messages will consist of stock alerts, news stories, and partner advertisements/offers. Consent is not a condition of the purchase of any goods or services. Text HELP for help/customer support. Unsubscribe at any time by replying "STOP" to any text message that you receive from MarketBeat or by visiting our mailing preferences page. Read our full terms of service and privacy policy. JSPRW Stock News HeadlinesAnalysts Have Conflicting Sentiments on These Healthcare Companies: Keros Therapeutics (KROS), Jasper Therapeutics (JSPR) and Corvus Pharmaceuticals (CRVS)May 17 at 12:09 PM | theglobeandmail.comTD Cowen downgrades Jasper Therapeutics (JSPR)May 16, 2026 | msn.comMusk's acquisition pattern points to ONE stockMusk needed solar - he acquired SolarCity. Needed data - he bought Twitter. The pattern is clear: when a supplier becomes mission-critical, Musk acquires. Right now, one small power infrastructure company is building the equipment his $1.75 trillion empire literally can't run without. Dylan Jovine has the name and ticker. | Behind the Markets (Ad)Jasper Therapeutics Inc : JSPRWMay 15, 2026 | 247wallst.comJasper Therapeutics (JSPR) price target decreased by 13.33% to 7.73May 14, 2026 | msn.comEvercore ISI Lowers its Price Target on Jasper Therapeutics (JSPR) to $7April 7, 2026 | finance.yahoo.comJasper Therapeutics shares rise 5% on clinical updates despite Q4 lossMarch 31, 2026 | msn.comJasper Therapeutics (JSPR) price target decreased by 30.92% to 8.92March 27, 2026 | msn.comSee More Headlines JSPRW Stock Analysis - Frequently Asked Questions How have JSPRW shares performed this year? Jasper Therapeutics' stock was trading at $0.0401 at the start of the year. Since then, JSPRW shares have decreased by 66.3% and is now trading at $0.0135. How do I buy shares of Jasper Therapeutics? Shares of JSPRW stock can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Charles Schwab, E*TRADE, Fidelity, and Vanguard Brokerage Services. Company Calendar Today5/19/2026Next Earnings (Estimated)8/07/2026Get Stock Alerts Health Indicator TradeSmith's Health IndicatorA long-term volatility-based measure designed for securities held 12 months or longer.Green: Strong and healthy uptrend with normal pullbacks.Yellow: Significant pullback but still within expected volatility.Red: Dropped beyond expected volatility; considered unhealthy. Red Zone (1w+) 1-Year History May 25 Aug 25 Nov 25 Feb 26 May 26 For the last 7 days, JSPRW's financial health has been in the Red zone, according to TradeSmith. Industry, Sector and Symbol Stock ExchangeNASDAQ SectorMedical Industry Biotechnology Sub-IndustryPharmaceutical Products Current SymbolNASDAQ:JSPRW CIK1788028 WebN/A Phone650-549-1400FaxN/AEmployees20Year FoundedN/AProfitability EPS (Trailing Twelve Months)N/A Trailing P/E RatioN/A Forward P/E RatioN/A P/E GrowthN/ANet IncomeN/A Net MarginsN/A Pretax MarginN/A Return on EquityN/A Return on AssetsN/A Debt Debt-to-Equity RatioN/A Current RatioN/A Quick RatioN/A Sales & Book Value Annual SalesN/A Price / SalesN/A Cash FlowN/A Price / Cash FlowN/A Book ValueN/A Price / BookN/AMiscellaneous Outstanding SharesN/AFree FloatN/AMarket CapN/A OptionableNot Optionable BetaN/A 7 Stocks That Could Be Bigger Than Tesla, Nvidia, and GoogleLooking for the next FAANG stock before everyone has heard about it? Click the link to see which stocks MarketBeat analysts think might become the next trillion dollar tech company.Get This Free Report This page (NASDAQ:JSPRW) was last updated on 5/20/2026 by MarketBeat.com Staff. From Our PartnersI’m sounding the alarmMeta is cutting 10% of its workforce. Microsoft offered voluntary retirement to 7% of U.S. employees. Oracle, ...Porter & Company | SponsoredYour book attachedVeteran trader Bill Poulos is giving away his 'Simple Options Trading For Beginners' book - normally $29.97 - ...Profits Run | SponsoredThe one number Musk can't hide in the S-1When SpaceX files its S-1 in June, one number will stand out - power consumption. Running 1 million GPUs requi...Behind the Markets | SponsoredHe doesn't buy gold. He just profits from it.Former hedge fund manager Larry Benedict generated $274 million in profits - and Barron's ranked his fund in t...Brownstone Research | SponsoredHow to Access Elon’s “Monster” Interest RateMost Americans earn just 0.4% on their savings - that's $40 a year on $10,000. A new banking alternative is of...InvestorPlace | SponsoredThe “tell” for the end of the AI boomThe real question about AI stocks in 2026 isn't whether to own them - it's knowing exactly when to get in and ...Stansberry Research | SponsoredBIGGER than the SpaceX IPO?Jon Najarian believes the SpaceX IPO - potentially arriving as soon as June 12th - may not even be the biggest...Banyan Hill Publishing | SponsoredAfter June 1, don't say I didn't warn youMacroeconomic Strategist Dr. Mark Skousen of The Oxford Club says one date should be at the top of every inves...The Oxford Club | Sponsored Adding Choose a watchlist: Watchlist Adding You have already added ten stocks to your watchlist. Upgrade to MarketBeat All Access to add more stocks to your watchlist. Adding Jasper Therapeutics, Inc. Please log in to your account or sign up in order to add this asset to your watchlist. Share Jasper Therapeutics With A Colleague Link copied to clipboard. Get 30 Days of MarketBeat All Access for Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools. Start Your 30-Day Trial MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Your Password: Log In Email Me a Login Link or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Choose a Password: Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
